Scarica l'app Stockscreener
2.63
0.77%
0.02
Dopo l'orario di chiusura:
2.65
0.02
+0.76%
Precedente Chiudi:
$2.61
Aprire:
$2.67
Volume 24 ore:
6,695
Relative Volume:
0.18
Capitalizzazione di mercato:
$44.78M
Reddito:
$1.02M
Utile/perdita netta:
$-36.14M
Rapporto P/E:
-0.2561
EPS:
-10.27
Flusso di cassa netto:
$-18.50M
1 W Prestazione:
-9.31%
1M Prestazione:
-15.97%
6M Prestazione:
-10.24%
1 anno Prestazione:
-35.70%
Intervallo 1D:
$2.63
$2.69
Intervallo di 1 settimana:
$2.60
$3.04
Portata 52W:
$2.285
$4.34
OncoCyte Corporation Stock (OCX) Company Profile
Nome
OncoCyte Corporation
Settore
Industria
Telefono
510-775-0515
Indirizzo
1010 Atlantic Avenue, Suite 102, Alameda, CA
Confronta OCX con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
| OCX | 2.63 | 44.78M | 1.02M | -36.14M | -18.50M | -10.27 |
| VRTX | 467.01 | 119.87B | 10.63B | -479.80M | -1.35B | 13.33 |
| REGN | 762.00 | 83.27B | 13.85B | 4.65B | 3.32B | 35.06 |
| ARGX | 567.90 | 33.96B | 1.86B | -40.29M | -1.28B | -4.16 |
| ALNY | 232.27 | 30.18B | 2.09B | -332.26M | 16.06M | -4.14 |
| BNTX | 101.87 | 24.42B | 3.30B | -501.07M | 1.03B | 11.54 |
OncoCyte Corporation Stock (OCX) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2022-05-24 | Downgrade | Stephens | Overweight → Equal-Weight |
| 2022-03-14 | Downgrade | KeyBanc Capital Markets | Overweight → Sector Weight |
| 2022-01-07 | Iniziato | Stephens | Overweight |
| 2022-01-06 | Ripresa | Piper Sandler | Overweight |
| 2021-03-17 | Ripresa | Needham | Buy |
| 2021-01-07 | Aggiornamento | The Benchmark Company | Speculative Buy → Buy |
| 2020-12-16 | Aggiornamento | Piper Sandler | Neutral → Overweight |
| 2020-11-30 | Iniziato | BTIG Research | Buy |
| 2020-11-10 | Iniziato | KeyBanc Capital Markets | Overweight |
| 2020-07-30 | Reiterato | The Benchmark Company | Speculative Buy |
| 2020-07-01 | Downgrade | Piper Sandler | Overweight → Neutral |
| 2020-06-30 | Downgrade | Chardan Capital Markets | Buy → Neutral |
| 2020-06-02 | Iniziato | Needham | Buy |
| 2019-02-13 | Iniziato | Piper Jaffray | Overweight |
| 2019-01-29 | Aggiornamento | Janney | Neutral → Buy |
| 2018-12-19 | Ripresa | Lake Street | Buy |
Mostra tutto
OncoCyte Corporation Borsa (OCX) Ultime notizie
PURA VIDA INVESTMENTS, LLC Expands Stake in OncoCyte Corp - GuruFocus.com
OncoCyte Corporation (NASDAQ:OCX) Q3 2024 Earnings Call Transcript - Insider Monkey
OncoCyte: Q3 Earnings Snapshot - Darien Times
OncoCyte Corp (OCX) Q3 2024 Earnings Call Highlights: Progress i - GuruFocus.com
OncoCyte Corp (OCX) Q3 2024 Earnings Call Highlights: Progress in Transplant Testing and ... - Yahoo Finance
OncoCyte Corp Reports Q3 2024 Earnings and Strategic Updates - TipRanks
OncoCyte Corp (OCX) Q3 2024 Earnings: EPS of -$0.98 Misses Estimates, Revenue Falls Short at $115,000 - GuruFocus.com
Oncocyte Reports Commercial Launch Progress; On Track to Sign 20 Transplant Centers by End of 2025 - The Manila Times
Oncocyte Corporation (OCX) Quarterly 10-Q Report - Quartzy
What to Expect from OncoCyte's Earnings - Benzinga
Oncocyte To Announce Third Quarter 2024 Financial Results on Nov. 12 - ForexTV.com
OncoCyte (NASDAQ:OCX) Coverage Initiated by Analysts at StockNews.com - MarketBeat
StockNews.com Initiates Coverage on OncoCyte (NASDAQ:OCX) - MarketBeat
Oncocyte Announces Participation in the LD Micro Main Event XVII Conference in Los Angeles - The Manila Times
Oncocyte Corp expands equity incentive plan - Investing.com India
Oncocyte Corp expands equity incentive plan By Investing.com - Investing.com Australia
OncoCyte shares maintain Buy rating from Needham By Investing.com - Investing.com Nigeria
OncoCyte shares maintain Buy rating from Needham - Investing.com
OncoCyte Corp (OCX) Q2 2024 Earnings Call Highlights: Strategic Advances Amidst Financial Challenges - Yahoo Finance
Oncocyte reports breakthrough in breast cancer diagnostics - Investing.com
Oncocyte's DetermaIO Immuno-Oncology Assay Predicts Response to Atezolizumab in Phase 2 Clinical Trial - The Manila Times
Oncocyte’s DetermaIO Immuno-Oncology Assay Predicts Response to Atezolizumab in Phase 2 Clinical Trial - StockTitan
Broadwood Partners L.P. buys Oncocyte shares for $3.88 million By Investing.com - Investing.com Australia
Oncocyte CFO acquires $99,999 worth of company shares By Investing.com - Investing.com South Africa
Oncocyte CFO acquires $99,999 worth of company shares - Investing.com
Broadwood Partners L.P. buys Oncocyte shares for $3.88 million - Investing.com
OncoCyte Secures Funding Through Private Share Sale - Yahoo Finance
OncoCyte Corporation announced that it expects to receive $10.203435 million in funding from Bio-Rad Laboratories, Inc. - Marketscreener.com
LENSAR reports inducement grants - Medical Buyer
Oncocyte Corporation enters into securities purchase agreement - Medical Buyer
Oncocyte Signs Leading Transplant Centers in US and Germany - The Manila Times
Oncocyte Corporation Announces $10.2 Million Private Placement of Securities Priced At-The-Market Under Nasdaq Rules - ForexTV.com
Sandfire Resources America Inc. Announces Incentive Plan Grants - The Manila Times
Micron Technology (MU-Q) QuotePress Release - The Globe and Mail
Breast Biopsy Devices Market 2024 – Industry Scenario, Strategies, Growth Factors and Forecast 2032 | OncoCyte Corporation, Benetec - 대구포스트
Breast Cancer Predictive Genetic Testing Market 2024 Key Stakeholders, CAGR, Growth Factors and Forecast 2032 | OncoCyte Corporation, Myriad Genetics - 대구포스트
OncoCyte Corporation Azioni (OCX) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
3.66%
1.11%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):